WO2009051201A1 - 抗bst2抗体 - Google Patents
抗bst2抗体 Download PDFInfo
- Publication number
- WO2009051201A1 WO2009051201A1 PCT/JP2008/068794 JP2008068794W WO2009051201A1 WO 2009051201 A1 WO2009051201 A1 WO 2009051201A1 JP 2008068794 W JP2008068794 W JP 2008068794W WO 2009051201 A1 WO2009051201 A1 WO 2009051201A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- bst2d
- bst2
- tissue
- specifically
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2008312858A AU2008312858A1 (en) | 2007-10-16 | 2008-10-16 | Anti-BST2 antibody |
JP2009538149A JP5558825B2 (ja) | 2007-10-16 | 2008-10-16 | 抗bst2抗体 |
CN200880122043.XA CN101952426B (zh) | 2007-10-16 | 2008-10-16 | 抗bst2抗体 |
CA2702939A CA2702939A1 (en) | 2007-10-16 | 2008-10-16 | Anti-bst2 antibody |
UAA201005531A UA105760C2 (uk) | 2007-10-16 | 2008-10-16 | Антитіло проти bst2 |
US12/738,285 US8529896B2 (en) | 2007-10-16 | 2008-10-16 | Anti-BST2 antibody |
MX2010004251A MX2010004251A (es) | 2007-10-16 | 2008-10-16 | Anticuerpo anti-bst2. |
BRPI0817427A BRPI0817427A8 (pt) | 2007-10-16 | 2008-10-16 | anticorpo anti-bst2 |
EP08838804A EP2210939A4 (en) | 2007-10-16 | 2008-10-16 | ANTIBODY ANTI-BST2 |
NZ585394A NZ585394A (en) | 2007-10-16 | 2008-10-16 | Anti-bst2 antibody |
IL205073A IL205073A (en) | 2007-10-16 | 2010-04-14 | 2 bst antibodies, methods of making them, medicinal preparations containing them and their use |
HK11107441.7A HK1153502A1 (en) | 2007-10-16 | 2011-07-18 | Anti-bst2 antibody bst2 |
US13/973,930 US20130336967A1 (en) | 2007-10-16 | 2013-08-22 | Anti-bst2 antibody |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007269470 | 2007-10-16 | ||
JP2007-269470 | 2007-10-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009051201A1 true WO2009051201A1 (ja) | 2009-04-23 |
Family
ID=40567462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/068794 WO2009051201A1 (ja) | 2007-10-16 | 2008-10-16 | 抗bst2抗体 |
Country Status (15)
Country | Link |
---|---|
US (2) | US8529896B2 (ja) |
EP (1) | EP2210939A4 (ja) |
JP (1) | JP5558825B2 (ja) |
KR (1) | KR20100090258A (ja) |
CN (2) | CN104031150A (ja) |
AU (1) | AU2008312858A1 (ja) |
BR (1) | BRPI0817427A8 (ja) |
CA (1) | CA2702939A1 (ja) |
HK (1) | HK1153502A1 (ja) |
IL (1) | IL205073A (ja) |
MX (1) | MX2010004251A (ja) |
NZ (1) | NZ585394A (ja) |
RU (1) | RU2010119450A (ja) |
UA (1) | UA105760C2 (ja) |
WO (1) | WO2009051201A1 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8771693B2 (en) | 2009-10-27 | 2014-07-08 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
CN103702967A (zh) | 2011-03-14 | 2014-04-02 | 貝丝以色列女执事医疗中心 | 用于治疗增殖性病症的方法和组合物 |
US10487114B2 (en) | 2011-04-27 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof |
WO2012162698A1 (en) | 2011-05-26 | 2012-11-29 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the treatment of immune disorders |
US9730941B2 (en) | 2012-06-07 | 2017-08-15 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the inhibition of Pin1 |
US20150299315A1 (en) * | 2012-10-22 | 2015-10-22 | Becton, Dickinson And Company | Non-b-lineage cells capable of producing antibody |
US9688747B2 (en) | 2013-03-15 | 2017-06-27 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
US9968579B2 (en) | 2014-07-17 | 2018-05-15 | Beth Isreal Deaconess Medical Center, Inc. | ATRA for modulating Pin1 activity and stability |
WO2016011265A2 (en) | 2014-07-17 | 2016-01-21 | Beth Israel Deaconess Medical Center, Inc. | Biomarkers for pin1-associated disorders |
EP3171892B1 (en) | 2014-07-22 | 2021-11-24 | Apollomics Inc. | Anti-pd-1 antibodies |
JP6909153B2 (ja) | 2014-08-05 | 2021-07-28 | アポロミクス インコーポレイテッド | 抗pd−l1抗体 |
US10548864B2 (en) | 2015-03-12 | 2020-02-04 | Beth Israel Deaconess Medical Center, Inc. | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions |
CN107619443B (zh) * | 2016-07-14 | 2020-08-14 | 深圳宾德生物技术有限公司 | 抗人和鼠cd317的单克隆抗体及其制备方法和应用 |
WO2021257894A1 (en) * | 2020-06-19 | 2021-12-23 | Board Of Regents, The University Of Texas System | Anti-bst2 antibodies targeting bst2 long isoform |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998035698A1 (fr) | 1997-02-12 | 1998-08-20 | Chugai Seiyaku Kabushiki Kaisha | Remedes contre les tumeurs lymphocitaires |
WO1999043803A1 (fr) | 1998-02-25 | 1999-09-02 | Chugai Seiyaku Kabushiki Kaisha | Gene codant pour la proteine antigenique hm1.24 et son promoteur |
WO2002057316A1 (fr) * | 2000-12-28 | 2002-07-25 | Kirin Beer Kabushiki Kaisha | Nouvel anticorps monoclonal |
WO2002064159A1 (en) | 2001-02-07 | 2002-08-22 | Chugai Seiyaku Kabushiki Kaisha | Remedies for tumor in hematopoietic organs |
WO2002084290A1 (fr) * | 2001-04-13 | 2002-10-24 | Chugai Seiyaku Kabushiki Kaisha | Procede permettant de quantifier l'expression d'antigenes |
WO2005034994A1 (ja) | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 固形腫瘍治療剤 |
WO2006008886A1 (ja) | 2004-06-11 | 2006-01-26 | Ginkgo Biomedical Research Institute Co., Ltd. | インターフェロン産生細胞の活性調節剤 |
WO2006013923A1 (ja) | 2004-08-05 | 2006-02-09 | Ginkgo Biomedical Research Institute Co., Ltd. | 自己免疫疾患を伴う関節炎の治療剤 |
WO2006054748A1 (ja) * | 2004-11-22 | 2006-05-26 | Ginkgo Biomedical Research Institute Co., Ltd. | 腎炎の治療剤 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US305121A (en) * | 1884-09-16 | Razor-strop | ||
TW442493B (en) * | 1993-10-15 | 2001-06-23 | Toshio Hirano | A membrane protein polypeptide having pre-B cell growth-supporting ability and a gene thereof |
US20080299128A1 (en) | 2006-06-20 | 2008-12-04 | Myung Kim | Effect of Bst2 on inflammation |
-
2008
- 2008-10-16 BR BRPI0817427A patent/BRPI0817427A8/pt not_active IP Right Cessation
- 2008-10-16 NZ NZ585394A patent/NZ585394A/en not_active IP Right Cessation
- 2008-10-16 RU RU2010119450/10A patent/RU2010119450A/ru unknown
- 2008-10-16 US US12/738,285 patent/US8529896B2/en not_active Expired - Fee Related
- 2008-10-16 EP EP08838804A patent/EP2210939A4/en not_active Withdrawn
- 2008-10-16 CN CN201410162825.3A patent/CN104031150A/zh active Pending
- 2008-10-16 JP JP2009538149A patent/JP5558825B2/ja not_active Expired - Fee Related
- 2008-10-16 WO PCT/JP2008/068794 patent/WO2009051201A1/ja active Application Filing
- 2008-10-16 AU AU2008312858A patent/AU2008312858A1/en not_active Abandoned
- 2008-10-16 CN CN200880122043.XA patent/CN101952426B/zh not_active Expired - Fee Related
- 2008-10-16 MX MX2010004251A patent/MX2010004251A/es active IP Right Grant
- 2008-10-16 CA CA2702939A patent/CA2702939A1/en not_active Abandoned
- 2008-10-16 KR KR1020107010635A patent/KR20100090258A/ko not_active Application Discontinuation
- 2008-10-16 UA UAA201005531A patent/UA105760C2/uk unknown
-
2010
- 2010-04-14 IL IL205073A patent/IL205073A/en not_active IP Right Cessation
-
2011
- 2011-07-18 HK HK11107441.7A patent/HK1153502A1/xx not_active IP Right Cessation
-
2013
- 2013-08-22 US US13/973,930 patent/US20130336967A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998035698A1 (fr) | 1997-02-12 | 1998-08-20 | Chugai Seiyaku Kabushiki Kaisha | Remedes contre les tumeurs lymphocitaires |
WO1999043803A1 (fr) | 1998-02-25 | 1999-09-02 | Chugai Seiyaku Kabushiki Kaisha | Gene codant pour la proteine antigenique hm1.24 et son promoteur |
WO2002057316A1 (fr) * | 2000-12-28 | 2002-07-25 | Kirin Beer Kabushiki Kaisha | Nouvel anticorps monoclonal |
WO2002064159A1 (en) | 2001-02-07 | 2002-08-22 | Chugai Seiyaku Kabushiki Kaisha | Remedies for tumor in hematopoietic organs |
WO2002084290A1 (fr) * | 2001-04-13 | 2002-10-24 | Chugai Seiyaku Kabushiki Kaisha | Procede permettant de quantifier l'expression d'antigenes |
WO2005034994A1 (ja) | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 固形腫瘍治療剤 |
WO2006008886A1 (ja) | 2004-06-11 | 2006-01-26 | Ginkgo Biomedical Research Institute Co., Ltd. | インターフェロン産生細胞の活性調節剤 |
WO2006013923A1 (ja) | 2004-08-05 | 2006-02-09 | Ginkgo Biomedical Research Institute Co., Ltd. | 自己免疫疾患を伴う関節炎の治療剤 |
WO2006054748A1 (ja) * | 2004-11-22 | 2006-05-26 | Ginkgo Biomedical Research Institute Co., Ltd. | 腎炎の治療剤 |
Non-Patent Citations (26)
Title |
---|
DALBADIE-MCFARLAND, G. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 79, 1982, pages 6409 - 6413 |
GOTO, T. ET AL.: "A novel membrane antigen selectively expressed on terminally differentiated human B cells", BLOOD, vol. 84, 1994, pages 1922 - 1930, XP000921004 * |
HASHIMOTO-GOTOH, T. ET AL., GENE, vol. 152, 1995, pages 271 - 275 |
ISHIDA ET AL., CLONING AND STEM CELLS, vol. 4, 2002, pages 85 - 95 |
ISHIKAWA, J. ET AL.: "Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth", GENOMICS, vol. 26, 1995, pages 527 - 534, XP004828668 * |
J. EXP. MED., vol. 108, 1995, pages 945 |
KAWAI, SHIGETO ET AL.: "Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models", ONCOLOGY REPORTS, vol. 15, 2006, pages 361 - 367, XP008115679 * |
KOISHIHARA Y ET AL., BLOOD, vol. 92, no. S, 1998, pages 107 |
KRAMER W; FRITZ HJ, METHODS. ENZYMOL., vol. 154, 1987, pages 350 - 367 |
KRAMER, W. ET AL., NUCLEIC ACIDS RES., vol. 12, 1984, pages 9441 - 9456 |
KRETZSCHMAR T. ET AL., CURR OPIN BIOTECHNOL., vol. 13, no. 6, December 2002 (2002-12-01), pages 598 - 602 |
KUNKEL, METHODS ENZYMOL., vol. 85, 1988, pages 2763 - 2766 |
KUNKEL, TA, PROC NATL ACAD SCI USA., vol. 82, 1985, pages 488 - 492 |
MARK, D. F., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 5662 - 5666 |
MCCAFFERTY J. ET AL., NATURE, vol. 348, 1990, pages 552 - 554 |
OHTOMO T. ET AL., BIOCHEM BIOPHYS RES COMMUN., vol. 258, no. 3, 1999, pages 583 - 91 |
OHTOMO, T. ET AL.: "Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 258, 1999, pages 583 - 591, XP002950705 * |
OZAKI S. ET AL., BLOOD, vol. 90, no. 8, 1997, pages 3179 - 86 |
OZAKI, S. ET AL.: "Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24", BLOOD, vol. 90, 1997, pages 3179 - 3186, XP002912305 * |
PROC. NATL. ACAD. SCI. USA, vol. 60, 1968, pages 1275 |
PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220 |
See also references of EP2210939A4 |
VALLE ET AL., NATURE, vol. 291, 1981, pages 358 - 340 |
WANG, A. ET AL., SCIENCE, vol. 224, pages 1431 - 1433 |
ZOLLER, M. J.; SMITH, M., NUCLEIC ACIDS RESEARCH, vol. 10, 1982, pages 6487 - 6500 |
ZOLLER, MJ.; SMITH, M., METHODS ENZYMOL., vol. 100, 1983, pages 468 - 500 |
Also Published As
Publication number | Publication date |
---|---|
EP2210939A4 (en) | 2012-08-08 |
CA2702939A1 (en) | 2009-04-23 |
NZ585394A (en) | 2012-05-25 |
AU2008312858A1 (en) | 2009-04-23 |
IL205073A (en) | 2014-07-31 |
BRPI0817427A2 (pt) | 2015-06-16 |
MX2010004251A (es) | 2010-08-30 |
US20100278832A1 (en) | 2010-11-04 |
US20130336967A1 (en) | 2013-12-19 |
EP2210939A1 (en) | 2010-07-28 |
US8529896B2 (en) | 2013-09-10 |
CN104031150A (zh) | 2014-09-10 |
CN101952426B (zh) | 2014-04-16 |
IL205073A0 (en) | 2010-11-30 |
RU2010119450A (ru) | 2011-11-27 |
UA105760C2 (uk) | 2014-06-25 |
JPWO2009051201A1 (ja) | 2011-03-03 |
HK1153502A1 (en) | 2012-03-30 |
BRPI0817427A8 (pt) | 2019-01-29 |
CN101952426A (zh) | 2011-01-19 |
JP5558825B2 (ja) | 2014-07-23 |
KR20100090258A (ko) | 2010-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009051201A1 (ja) | 抗bst2抗体 | |
WO2007109376A3 (en) | Anti-tumor cell antigen antibody therapeutics | |
CY1118880T1 (el) | Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
EP3301117A3 (en) | Specific binding proteins and uses thereof | |
WO2011041319A8 (en) | Specific binding proteins and uses thereof | |
EA201190041A1 (ru) | Человеческие аутоантитела против альфа-синуклеина | |
BR112013004266A2 (pt) | anticorpos anti-ox40 e métodos de uso dos mesmos. | |
WO2008076560A3 (en) | Human monoclonal antibodies to btla and methods of use | |
WO2008108803A3 (en) | Immune cell biosensors and methods of using same | |
WO2007067992A3 (en) | Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 | |
CR20120506A (es) | PROTEÍNAS QUE SE UNEN AL TNF-a | |
WO2006085984A3 (en) | Immune cell biosensors and methods of using same | |
IN2014CN03936A (ja) | ||
WO2006086561A3 (en) | Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus | |
WO2011050106A3 (en) | Anti-cd3 antibody dosing in autoimmune disease | |
EA201290849A1 (ru) | Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
WO2007111875A3 (en) | Methods for diagnosing and treating kidney and colorectal cancer | |
WO2010031749A9 (en) | Compositions and methods for detecting tlr3 | |
WO2010036031A3 (en) | Pauf-specific human monoclonal antibody, pharmaceutical composition for treating cancer comprising the same and method for detecting cancer using the same | |
WO2008120006A3 (en) | Diagnostic assay | |
WO2010028820A3 (en) | Peripheral zone tumor cells, methods for their preparation and use | |
WO2010053772A3 (en) | Disease-associated antigens and methods of use thereof | |
WO2012077983A3 (ko) | Ape1/ref-1을 함유하는 방광암 진단용 조성물, 및 이를 이용한 방광암 진단 키트 | |
WO2011050104A3 (en) | Methods of using anti-cd3 antibodies to prevent weight gain | |
WO2009145478A3 (ko) | 녹내장 진단용 키트 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880122043.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08838804 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2009538149 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 205073 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2702939 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2010/004251 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008312858 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3243/DELNP/2010 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008838804 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20107010635 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 585394 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: A20100732 Country of ref document: BY |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010119450 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2008312858 Country of ref document: AU Date of ref document: 20081016 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12738285 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0817427 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100416 |